The reasons behind Big Data's rise

Fiscal concerns are paramount in the rise of Big Data within healthcare, according to a recent McKinsey analysis, but clinical trends also play a role.

Healthcare expenses are now 17.6% of GDP—nearly $600 billion more than the expected benchmark for a nation of the United States's size and wealth, notes the consultancy, which did a regression analysis of countries' income and spending data.

Payors are seeking to clamp costs by shifting from fee-for-service compensation to risk-sharing arrangements that prioritize outcomes, as well as partnering with pharma and basing reimbursement on drugs' ability to improve health. McKinsey also cites the move toward evidence-based medicine, with its reliance on aggregating individual data sets into big-data algorithms.

Healthcare could soon catch up to other sectors in using Big Data, as first movers in the data sphere are already achieving positive results.
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.